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Abstract The success of stem cell therapy is highly depen-
dent on accurate delivery of stem cells to the target site of
interest. Possible ways to track the distribution of MSCs
in vivo include the use of reporter genes or nanoparticles.
The U.S. Food and Drug Administration (FDA) has approved
ferumoxytol (Feraheme® [USA], Rienso® [UK]) as a treat-
ment for iron deficiency anemia. Ferumoxytol is an ultrasmall
superparamagnetic iron oxide nanoparticle (USPIO) that has
recently been used to track the fate of transplanted cells using
magnetic resonance imaging (MRI). The major objectives of
this study were to demonstrate the feasibility of labeling
hUCB-MSCs with ferumoxytol and to observe, through
MRI, the engraftment of ferumoxytol-labeled human
umbilical cord blood-derived mesenchymal stem cells
(hUCB-MSCs) delivered via stereotactic injection into the
hippocampi of a transgenic mouse model of familial
Alzheimer’s disease (5XFAD). Ferumoxytol had no toxic ef-
fects on the viability or stemness of hUCB-MSCs when
assessed in vitro. Through MRI, hypointense signals were
discernible at the site where ferumoxytol-labeled human
MSCs were injected. Iron-positive areas were also observed
in the engrafted hippocampi. The results from this study sup-
port the use of nanoparticle labeling to monitor transplanted
MSCs in real time as a follow-up for AD stem cell therapy in
the clinical field.
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Introduction
The curative and regenerative properties of stem cells have
marked them as promising candidates as novel therapeutic
agents for various neurodegenerative diseases [1–3]. Out of
the wide range of neurodegenerative diseases, stem cell appli-
cation seems to be particularly appealing for Alzheimer’s dis-
ease (AD) [4–6]. Considered the most widely known and
common type of dementia, the pathology of AD is complex
and the causes are multifactorial [7, 8]. With such complica-
tions present, mesenchymal stem cells (MSCs) have become a
promising therapeutic agent for AD stem cell therapy because
of the multiple functional roles that they can mediate through
their paracrine activities [9–11]. The multiple roles of MSCs,
ranging from anti-apoptosis to anti-inflammation, make them
ideal for the treatment of heterogeneous diseases such as AD
where they can target more than one mechanism [12–15].
Using a transgenic AD mouse model, our group has observed
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the removal of amyloid plaques and acceleration of endoge-
nous neurogenesis through treatment with MSCs [16–18].
In order for these MSCs to exert their therapeutic benefits
at the target site, the delivery route is of key concern [19].
Previously, our group has reported that MSC engraftment in
the brains of transgenic AD mice is very low when cells are
delivered through the intra-venous [20] and intra-arterial
routes [21]. In contrast, intra-parenchymal administration is
invasive, although maximal engraftment of MSCs can be
achieved. In parallel to our pre-clinical studies [16, 17, 20],
our group has also conducted a phase I clinical trial involving
the intra-parenchymal administration of human umbilical cord
blood-derived mesenchymal stem cells (hUCB-MSCs) into
the hippocampus and precuneus of AD patients [22].
Through this study, we were able to confirm the safety
and feasibility of implanting cells directly into the brain
parenchyma. However, one limitation was that the dis-
tribution of the transplanted cells could not be assessed
through non-invasive means.
Cells can be observed non-invasively using two methods: a
direct method that involves labeling stem cells with nanopar-
ticles and an indirect imaging method that utilizes reporter
genes [23, 24]. Out of the various imaging modalities, mag-
netic resonance imaging (MRI) possesses several advantages
that make it suitable for cellular imaging, such as superior soft
tissue contrast and high resolution [25]. Cells can be labeled
with iron oxide nanoparticles to perform MRI [26, 27]. In
2009, the U.S. Food and Drug Administration (FDA) ap-
proved the use of ferumoxytol (Feraheme® [AMAG
Pharmaceuticals, USA], Rienso® [Takeda Inc., UK]),
an ultrasmall superparamagnetic iron oxide nanoparticle
(USPIO), as a treatment for iron deficiency anemia in
chronic kidney disease [28, 29]. Ferumoxytol (off-label
use) has been used widely in pre-clinical studies for
cellular imaging purposes [29–32].
Utilizing these characteristics of ferumoxytol, the ma-
jor objectives of this current study were first to investigate
the feasibility of labeling hUCB-MSCs with ferumoxytol
in vitro, and then to monitor in vivo engraftment of MSCs
through MRI. To reduce the risk of engraftment failure,
intra-parenchymal administration was chosen to non-
invasively image MSCs that had been directly delivered
into the hippocampus of the 5X familial Alzheimer’s dis-
ease (FAD) mouse model.
Materials and Methods
Ethical Statement
This study was reviewed and approved by the Institutional
Review Board (IRB) of Samsung Medical Center (IRB no.
2015–01-028). This research was also approved by the
Institutional Animal Care and Use Committee (IACUC) of
the Samsung Biomedical Research Institute (SBRI) at
Samsung Medical Center (SMC). The SBRI is an accredited
facility of the Association for Assessment and Accreditation
of Laboratory Animal Care International (AAALAC
International) and abides by the Institute of Laboratory
Animal Resources (ILAR) guide.
Cell Culture and Ferumoxytol Labeling
Human umbilical cord blood-derived mesenchymal stem cells
(hUCB-MSCs) acquired from Medipost Inc. (Biomedical
Research Institute Co., Ltd., Republic of Korea) were cultured
in minimum essential medium (MEM)α1× media (Gibco-
Invitrogen, Carlsbad, CA, USA) containing 10 % fetal bovine
serum (FBS; Biowest, Riverside, MO, USA) and 0.5 % gen-
tamicin (Thermo Fisher Scientific, Hudson, NH, USA) at
37 °C, 5 % CO2. Passage 6 cells were used for the study.
After reaching 80–90 % confluence, hUCB-MSCs were
washed with Dulbecco’s phosphate buffered saline (DPBS;
Biowest, Riverside, MO, USA) and labeled with ferumoxytol
as described previously [29, 33, 34]. Cells were treated with
serum-free MEMα1× medium containing heparin (4 U/mL;
JW Pharmaceuticals, Seoul, Republic of Korea), protamine
sulfate (80 μg/mL; Hanlim Pharmaceuticals, Republic of
Korea), and ferumoxytol (200 μg/mL; Rienso®, Takeda
Inc., Denmark, UK). These reagents are clinically available
and thus readily accessible for use. After 4 to 5 h, an equal
volume of medium supplemented with 20 % FBS was added
to give a final concentration of 2 U/mL heparin, 40 μg/mL
protamine sulfate, and 100 μg/mL ferumoxytol. Cells were
incubated for an additional 20 h at 37 °C, 5 % CO2.
Cell Viability Assay
hUCB-MSCs were initially seeded in six replicates of 96-well
plates at a density of 9.6 × 103 per well for 24 h. MSCs were
treated with 2 U/mL heparin and various doses of protamine
sulfate and ferumoxytol for an additional 24 h. After the incu-
bation period, cells were assayed for viability using the
Alamar blue assay (Sigma-Aldrich, St. Louis, MO, USA).
Cells were treated with the Alamar blue reagent for 3 h at
37 °C and 5%CO2, and fluorescence was read by a multiplate
reader (GloMax®-Multi Detection System; Promega,
Madison, WI, USA).
Prussian Blue Staining
Unlabeled and ferumoxytol-labeled hUCB-MSCs were
washed with DPBS (Biowest) and then fixed with 4 % para-
formaldehyde (Biosesang, Gyeonggi-do, Republic of Korea)
for 15 min at room temperature (RT). Cells were washed with
DPBS before staining. Paraffin blocks of the ferumoxytol-
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labeled hUCB-MSCs were prepared as described previously
[21]. Staining was performed as instructed by the manu-
facturer (NovaUltra Prussian Blue Stain Kit; IHC
WORLD, Woodstock, MD, USA). Stained slides were
scanned using Aperio Scan Scope AT and visualized
through the Aperio Image Scope program (Leica
Biosystems, Buffalo Grove, IL, USA).
Immunophenotyping
After 24 h, unlabeled and ferumoxytol-labeled hUCB-MSCs
were washed with DPBS and detached using 0.25 % trypsin
(Sigma-Aldrich). The surface antigens of unlabeled and
ferumoxytol-labeled hUCB-MSCs were phenotyped by stain-
ing the cells with FITC, PE, or APC-coupled antibodies for
15 min at RT. Anti-human antibodies against the following
proteins were used for fluorescence-activated cell sorting
(FACS): CD14, CD45, CD73, CD90, CD105, and HLA-DR
(BD Pharmingen, San Jose, CA, USA). IgG1 and IgG2a (BD
Pharmingen) were used as the corresponding mouse isotype
controls. Labeled cells were washed with DPBS, fixed with
1 % paraformaldehyde (PFA; Biosesang, Gyeonggi-do,
Republic of Korea), and analyzed by the MACSQuant®
Analyzer (Miltenyi Biotec, San Diego, CA, USA).
Trilineage Differentiation and Evaluation
Adipogenic differentiation was induced using the StemPro
Adipogenesis Differentiation Kit (Thermo Fisher Scientific).
hUCB-MSCs were labeled with ferumoxytol for 24 h in a 6-
well plate, washed three times with DPBS, and the media was
replaced with the adipogenic base medium. The medium was
changed twice a week for a total of 2 weeks. Cells were fixed
with 4 % PFA and stained with Oil Red O (Sigma-Aldrich). To
induce osteogenic differentiation, cells were first labeled with
ferumoxytol as described above and then cultured in osteogenic
base medium using the StemPro Osteogenesis Differentiation
Kit (Thermo Fisher Scientific). Themediumwas changed twice
a week for one week. After fixation using a solution containing
citrate and acetone, mineralized matrix was assessed by alka-
line phosphatase staining (Sigma-Aldrich).
Unlabeled and ferumoxytol-labeled cells were treated with
chondrogenic medium, which consisted of high-glucose
DMEM (Biowest) supplemented with 100 nM dexametha-
sone (Sigma-Aldrich), 50 mg/mL L-ascorbic acid (Sigma-
Aldrich), 100 mg/mL sodium pyruvate (Sigma-Aldrich),
40mg/mL L-proline (Sigma-Aldrich), 10 ng/mL transforming
growth factorβ3 (TGF-β3; R&DSystems,Minneapolis,MN,
USA), 500 ng/mL bone morphogenic protein 6 (BMP-6;
R&D Systems), and 50 mg/mL ITS+ premix (Becton
Dickinson, Franklin Lakes, NJ, USA). After induction of dif-
ferentiation for 4 weeks, cell pellets were collected and em-
bedded in OCT compound (Tissue-Tek, Torrance, CA, USA).
Sections of the pellets were prepared at 5-μm thickness using
a cryotome (Thermo Fisher Scientific) and stained with
Safranin-O (Biosesang). Stained slides were observed using
an inverted light microscope (U-HGLGPS, Olympus, Japan).
Experimental Animals
5XFAD transgenic AD mice that overexpress mutant human
APP(695) with the Swedish (K670 N, M671 L), Florida
(I716V), and London (V717I) familial Alzheimer’s disease
(FAD) mutations and human PS1 harboring two FAD muta-
tions, M146 L and L286 V, were purchased from Jackson
Laboratories (Bar Harbor, ME, USA). These transgenic mice
were crossed, and the offspring were genotyped by DNA ex-
traction from tail samples. These mice were fed ad libitum and
were also maintained in a 12 h light/12 h dark cycle. A total of
fifteen 7–8 month old mice were used for this study: sham
(n = 3), MR imaging right after injection (n = 3), post 1 day
(n = 3), 7 days (n = 3), and 14 days (n = 3).
Hippocampal Injections of Unlabeled
and Ferumoxytol-Labeled hUCB-MSCs
After labeling with ferumoxytol for 24 h, hUCB-MSCs were
washed three times: first with DPBS, second with DPBS con-
taining heparin (10 U/mL), and finally with DPBS again.
Cells were detached using 0.25 % Trypsin-EDTA (Gibco-
Invitrogen). Ferumoxytol-labeled hUCB-MSCs were resus-
pended in phenol red-free MEMα1× media (Gibco-
Invitrogen) prior to injection. Animals were stably positioned
on a stereotactic device (Harvard Apparatus, Holliston, MA,
USA) using ear bars. Coordinates of A/P − 1.94 mm,
M/L ± 1.00 mm, and D/V − 2.6 mm were used to perform
the sham operation, which only involved insertion and remov-
al of a Hamilton syringe needle (Hamilton Company, Reno,
NV) or injection of unlabeled (2 × 105 /3 μL), and/or
ferumoxytol-labeled hUCB-MSCs (2 × 105/3 μL) into the left
and right hippocampus of 5XFADmice, respectively, at a rate
of 0.5 μl/min. Following the infusion, a 5 min delay time was
provided before retracting the syringe needle. Mice were ini-
tially anesthetized with 5 % isoflurane (Hana Pharmaceutical
Co., Ltd., Seoul, Republic of Korea) and subsequently main-
tained under 2 % isoflurane during the whole procedure.
Magnetic Resonance Imaging
A 7 T/20 MRI System (Bruker-Biospin, Fällanden,
Switzerland) was used to acquire MR images of the phantom
cell samples and the mouse brain. Unlabeled and
ferumoxytol-labeled cells were mixed with 0.8 % agarose
(Bioplus, Gyeonggi-do, Republic of Korea) to prepare the
phantom samples. The tubes were filled with distilled water
to reduce background artifacts. MR images were obtained
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using a multislice multiecho (MSME) spin echo sequence with
the following parameters: repetition time (TR)/echo time
(TE) = 2500/14–230 msec, slice thickness = 0.7 mm, number
of averages = 4.MR images of the mouse brain were acquired as
described previously [ 21]. T2-weighted images were obtained
using the following parameters: TR/TE = 2500/20msec, number
of averages = 8, and slice thickness = 0.7 mm. AT2* gradient
echo (GRE) sequence was used to acquire MR images using the
following parameters: TR/TE = 303.805/18 msec, number of
averages =8, slice thickness = 0.7 mm, and flip angle
(FA) = 45°. Mice were anesthetized under 2 % isoflurane while
the MR images were obtained.
Tissue Fixation and Immunohistochemistry
At the respective time points, mice underwent MR imaging
and were sacrificed via cardiac perfusion. After fixation in 4%
PFA for 24 h, paraffin blocks were prepared, and 4-μm sec-
tions were cut using a microtome (Thermo Fisher Scientific).
Sections were deparaffinized, and Prussian blue staining was
conducted using the protocol described above. For immuno-
histochemical (IHC) staining, 1× citrate buffer, pH 6 (Dako,
Carpinteria, CA, USA) was first used to perform heat-induced
antigen retrieval. Immunofluorescence staining was per-
formed according to our previous report [21] using primary
antibodies against mitochondria (1:200; Millipore, Billerica,
MA, USA), ionized calcium binding adaptor molecule 1 (Iba-
1, 1:250; Wako Chemicals, Richmond, VA, USA), and glial
fibrillary acidic protein (GFAP, 1:1000; Abcam, Cambridge,
MA, USA). Alexa Fluor 546-conjugated donkey anti-mouse
(1:250; Life Technologies, Hudson, NH, USA), Alexa Fluor
488-conjugated donkey anti-goat (1:400; Jackson
ImmunoResearch Europe Ltd., Newmarket, UK), and Alexa
Fluor 546-conjugated donkey anti-rabbit (1:400; Life
Technologies, Hudson, NH, USA) were used as secondary
antibodies. Stained slides were observed using a confocal mi-
croscope (LSM700, Carl Zeiss AG, Jena, Germany).
Statistical Analysis
All data presented in the paper are expressed as mean ± stan-
dard error of mean (S.E.M.). A P value ≤0.05 was considered
statistically significant. Student’s t-test was used to investigate
the differences between groups.
Results
Characterization of Ferumoxytol-Labeled hUCB-MSCs
in vitro
Using the heparin-protamine sulfate-ferumoxytol nanocomplex
technique, blue staining was seen in the cytoplasm of hUCB-
MSCs labeled with ferumoxytol compared with the unlabeled
hUCB-MSCs (Fig. 1a). Differences in morphology of hUCB-
MSCs such as adherent, bipolar, and fibroblast-like characteris-
tics [35] were not noted following labeling (Fig. 1a). The effi-
ciency of ferumoxytol labeling of hUCB-MSCs was further ob-
served in the detached re-suspended state by creating cell paraffin
blocks (Fig. 1b). Unlike the unlabeled hUCB-MSCs, brown
staining was grossly observed from the pellet of ferumoxytol-
labeled hUCB-MSCs (Fig. 1c), a common observation for cells
labeled with iron oxide nanoparticles [36, 37]. The overall label-
ing efficiency was 85.84 ± 2.02 % (mean ± S.E.M.). To assess
alterations in cell viability, hUCB-MSCs were treated with a
constant dose of heparin and varying doses of protamine sulfate
and ferumoxytol. The cell viability percentages after treatment
with 10/100, 40/100, and 40/400 μg/mL of protamine sulfate/
ferumoxytol were 91.64 ± 3.66, 83.86 ± 4.58, and
84.19 ± 5.76 %, respectively (Fig. 1d). Labeling the cells did
not affect the overall viability of the cells; however, in-
creasing the concentration of protamine sulfate decreased
the viability by approximately 20 %. A possible explana-
tion is the toxic effects exerted by the positive charges of
protamine sulfate [38]. However, the overall viability was
still high probably due to the counteractive roles of hep-
arin on protamine sulfate [38].
According to the axial and sagittal MR images, of the aga-
rose-only, unlabeled, and ferumoxytol-labeled hUCB-MSC-
agarose phantom samples, a reduction in signal contrast was
detected from ferumoxytol- labeled hUCB-MSCs
(Supplementary Fig. S1A). When quantitatively measured,
the mean signal intensities of the agarose sample, unla-
beled, and ferumoxytol-labeled hUCB-MSCs were
168.33 ± 4.48, 151 ± 2.08, and 63.67 ± 6.34, respectively
(Supplementary Fig. S1B). This reduction in signal inten-
sity was statistically significant when the ferumoxytol-
labeled hUCB-MSCs were separately compared with the
agarose control (**P ≤ 0.01) and the unlabeled hUCB-
MSCs (**P ≤ 0.01) (Supplementary Fig. S1B). The dif-
ference between the unlabeled hUCB-MSCs and the
agarose-only sample was also statistically significant
(*P ≤ 0.05).
Differentiation Potential and Stemness
of Ferumoxytol-Labeled hUCB-MSCs
Trilineage differentiation was not affected by labeling hUCB-
MSCs with ferumoxytol. For both unlabeled (Fig. 2a) and
ferumoxytol-labeled hUCB-MSCs (Fig. 2b), induction of ad-
ipogenesis was demonstrated by the accumulation of lipid-
rich vacuoles inside the cells that were stained with Oil red
O (Fig. 2a, b). Osteogenic differentiation was observed in both
unlabeled and ferumoxytol-labeled cells that expressed alka-
line phosphatase (Fig. 2a, b). The expression of sulfated pro-
teoglycans was detected by Safranin O staining (Fig. 2 a, b).
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Through FACS, there were no discernible differences in the
expression of surface molecules between the unlabeled and
ferumoxytol-labeled hUCB-MSCs. The percentages of posi-
tive expression of surface molecules CD105, CD90, and
CD73 were 99.78 ± 0.09, 99.06 ± 0.44, and 99.92 ± 0.03 %,
respectively, for unlabeled hUCB-MSCs (Supplementary
Fig. S2A) and 99.98 ± 0.01, 98.43 ± 0.73, and 99.91 ± 0.07 %,
respectively, for ferumoxytol-labeled hUCB-MSCs
(Supplementary Fig. S2B). Both unlabeled and ferumoxytol-
labeled hUCB-MSCs lacked expression of the surface mole-
cules HLA-DR, CD45, and CD14 (Supplementary Fig. S2);
the expression percentages were ≤2 %, which met the minimal
criteria proposed by the International Society for Cellular
Therapy (ISCT) for MSCs [35, 39].
Fig. 1 Labeling hUCB-MSCs with Ferumoxytol. a Compared to
unlabeled cells where no iron-positive blue areas were evident, blue
staining could be observed in the cytoplasm of ferumoxytol–labeled
hUCB-MSCs. Scale bar =50 μm. b Co-localization of iron- (black solid
arrow) and ferumoxytol-labeled hUCB-MSCs (circular, pink) in a re-
suspended state. Scale bar =100 μm. c Brown staining could be
detected from the pellet of ferumoxytol-labeled hUCB-MSCs. Grid
=1 mm. d Cell viability of hUCB-MSCs treated with various
concentrations of protamine sulfate/ferumoxytol assessed using the
Alamar Blue assay (average of 4 independent experiments, *P ≤ 0.05
compared to the unlabeled control sample)
Fig. 2 Differentiation Potential of Ferumoxytol-Labeled hUCB-MSCs.
Adipogenic (Oil Red O staining), osteogenic (alkaline phosphatase), and
chondrogenic (Safranin O staining) differentiation were observed from
both (a) unlabeled and (b) ferumoxytol-labeled hUCB-MSCs. Oil Red O:
Scale bar =50 μm; Alkaline phosphatase and Safranin O = 100 μm
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Detection of Hypointense Signals from Transplantation
of Ferumoxytol-Labeled hUCB-MSCs in the Mouse
Hippocampus
The in vivoMR characteristics of ferumoxytol-labeled hUCB-
MSCs were preliminarily assessed by performing a sham sur-
gery and intra-parenchymal administration of ferumoxytol-
labeled MSCs into the right hippocampus. MR images were
acquired immediately after surgery. In the T2-weighted and
T2* GRE MR images, the sham group displayed a
hypointense (dark) vertical line extending downward from
the cortex, representing the location of the needle track
(Fig. 3a). However, the manifestation of the hypointense sig-
nal was clearly distinguishable from the group that received
ferumoxytol-labeled hUCB-MSC injections, which showed
hypointense signals that permeated or spread at the end of
the needle track and created a diagonal linear (T2-weighted)
or ovular (T2* GRE) appearance (Fig. 3b). The presence of
ferumoxytol-labeled hUCB-MSCs was confirmed through
Prussian blue staining (Fig. 3b).
Subsequently, engraftment of ferumoxytol-labeled hUCB-
MSCs was observed at post 1 day. MR images acquired at
1 day post injection displayed dark, hypointense signals in
the right hippocampus of 5XFAD mice where the
ferumoxytol-labeled hUCB-MSCs were injected (Fig. 4a).
Although a strong blooming effect was evident, the appear-
ance of the signal was similar to that from MR images ac-
quired immediately after the transplantation. Other than slight
hyperintense signals showing the site of needle puncture in the
T2-weighted MR images, no hypointense signals were detect-
ed in the left hippocampus, where unlabeled hUCB-MSCs
were administered (Fig.4a).
HumanMSC engraftment in both hippocampi (Fig. 4a) was
confirmed by IHC staining of human mitochondria (Fig. 4b).
Although the percentage of mitochondria-positive cells among
the total cells (Hoechst stained) was slightly higher in the right
hemisphere, the differences between the two hippocampi were
not statistically significant (Fig. 4c). In addition to corroborat-
ing human MSC engraftment, iron-positive areas were stained
blue in the right hippocampus by Prussian blue staining, where-
as none were discernible in the left hippocampus (Fig. 4d). The
absence of human cells in the dorsal 3rd ventricle (Fig. 5a) and
lateral ventricles of the left and right hemispheres (Fig. 5b, c)
confirmed the accuracy of the engraftment and suggested that
the cells did not migrate into ventricular regions by possible
back flow that may arise along the needle track.
No Infiltration of Inflammatory Cells into the Site ofMSC
Engraftment
Additional IHC staining using anti-Iba-1 (microglia/macro-
phage) and anti-GFAP (astrocyte) antibodies was performed
to evaluate inflammatory effects that may arise from injection
of unlabeled/ferumoxytol-labeled hUCB-MSCs and to cor-
roborate the source of the MR signal. Based on microscopic
evaluations, a dramatic difference in Iba-1 and GFAP expres-
sion was not evident between the left and right hippocampus
(Fig. 6a). Interestingly, very low or no expression of Iba-1 or
GFAP was apparent at the site of hUCB-MSC engraftment
(indicated with a white dotted line) in the right hippocampus,
which was confirmed by staining an adjacent slide using the
anti-mitochondria antibody (Fig. 6b). These observations
were quantitatively assessed, and the percentages of Iba-1
and GFAP–positive cells over the total number of cells
(Hoechst) were determined for both the left and right hippo-
campi (Fig. 6c). Compared to the left hemisphere, the percent-
ages of Iba-1 and GFAP were lower or similar, respectively, in
the right hippocampus. Although not investigated in detail, the
slightly higher engraftment percentage of MSCs in the right
hippocampus could have exerted more immunomodulatory
effects to contribute to the lower Iba-1 percentage in compar-
ison to the left hippocampus.
Persistence of Hypointense Signals at Prolonged Time
Points
With such observations made at post 1 day, a question that
arose was whether hypointense signals will be observed at the
Fig. 3 Differences in Hypointensities Generated from Sham-Operated
and Ferumoxytol-labeled hUCB-MSC Injected Mice. a A linear
hypointense signal from T2-weighted and T2* GRE images revealed
the puncture site and needle track. b In contrast, diffusion of
hypointense signals was discernible in the right hippocampus of mice
that received injections of ferumoxytol-labeled hUCB-MSCs. Prussian
blue stains revealed iron positive cells in the right hippocampus. Scale
bar: 80 μm
132 Stem Cell Rev and Rep (2017) 13:127–138
engraftment site past 1 day. Therefore, additional experiments
were conducted under the same experimental settings as the
post 1 day group, and the mice were monitored at 2 time
points: post 7 and 14 days. For both groups, at both post
7 days, the hypointense signal was consistently observed at
the right hippocampus (Fig. 7a, b). Especially discernible
from the T2* GRE images, the overall size of the signal was
decreased, when compared to the image acquired at post 1 day
Fig. 4 Post 1 DayMR Images Corroborated with IHC Staining. aA total
of 2 × 105 unlabeled or ferumoxytol labeled hUCB-MSCs were injected
into the left and right hippocampus, respectively, of 5XFAD mice.
According to the T2-weighted and T2* MR images acquired post
1 day, compared to the left hemisphere, hypointense signals could be
observed from the right hippocampus where ferumoxytol-labeled
hUCB-MSCs were administered. Left (L) = unlabeled hUCB-MSCs,
and right (R) = ferumoxytol-labeled hUCB-MSCs. b Human MSCs
were observed in both the left and right hippocampi using the anti-
mitochondria antibody. Scale bar: 20 μm. c Quantification of the
number of cells positive for anti-mitochondria staining over the total
number of Hoechst-positive cells (4 sections per hippocampus for each
mouse). d Iron deposits were detected by Prussian blue staining in the
right hippocampus. Scale bar: 90 μm
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Fig. 5 Absence of MSCs in the
Vascular Regions of the Mouse
Brain. No hUCB-MSCs (anti-
mitochondria antibody) were
discernible in the (a) dorsal 3rd
ventricle or in either the (b) left or
(c) right lateral ventricle. Scale
bar: dorsal 3rd ventricle: 50 μm,
lateral ventricles: 100 μm
Fig. 6 Inflammatory Cells are not Observed at the Sites of hUCB-MSC
Engraftment. a Iba-1 and GFAP expression was not observed at the
locations where hUCB-MSCs were transplanted in either the left or
right hippocampus. The white dotted line indicates the site of cell
engraftment. Scale bar: 100 μm. b An adjacent slide was stained using
the anti-mitochondria antibody to confirm the location of the cells
enclosed by the white dotted line. (C) Quantification of number of cells
positive for Iba-1 (left) or GFAP (right) over total number of Hoechst-
positive cells (4 sections per hippocampus for each mouse)
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(Fig. 7a, b). The size and appearance of the signal detected at
post 14 days resembled that observed at post 7 days (Fig. 7b).
Discussion
In this study, ferumoxytol-labeled hUCB-MSCs that were
engrafted in the hippocampus of 5XFAD transgenic AD mice
were observed using MRI with the hope of supporting the
application of this technique in AD stem cell therapy.
Although invasive brain penetration and confined cellular dis-
tribution are disadvantages of stereotactic delivery, themethod
is still a well-established technique that has been widely used
in small animals and allows for localization of cells at the
target site [40]. In our study, we targeted the hippocampi of
5XFAD transgenic mice that are known to develop high am-
yloid deposition at very early stages of disease progression
[41]. Considering these pathological features and the presence
of the blood brain barrier (BBB), intra-parenchymal adminis-
tration is preferred in the clinical settings; our group has
clinically confirmed the safety and feasibility of delivering
stem cells by utilizing this route in AD patients [22].
The first goal of this study was to demonstrate the feasibil-
ity of labeling hUCB-MSCs with ferumoxytol. Our results
were in agreement with past studies that supported the use of
the heparin-protamine sulfate-ferumoxytol nanocomplex as
an efficient labeling method [29, 30, 34]. We observed in vitro
ferumoxytol labeling of hUCB-MSCs in both adhered and
detached states. Iron-positive staining of detached
ferumoxytol-labeled hUCB-MSCs confirmed the stability of
ferumoxytol labeling even after multiple washings, centrifu-
gation, and re-suspension. In addition to efficient labeling,
ferumoxytol labeling did not negatively influence the expres-
sion of certain cell surface markers or the differentiation ca-
pabilities of hUCB-MSCs in vitro. The fibroblastic charac-
teristics and overall proliferation of the labeled cells were
not impaired [42, 43]. There are evidences of MSCs dif-
ferentiating into ectodermal lineages if pre-induced or in-
troduced to developmental cues in vivo [44, 45], but ex-
amining such potentials was not defined as the major ob-
jectives of this present study.
Fig. 7 Hypointense Signals Consistently Visualized at Extended Time
Points. MR images acquired up to (a) 7 and (b) 14 days post
transplantation. Similar to early time points, hypointense signals were
observed in the right hippocampus where the ferumoxtyol-labeled
hUCB-MSCs were transplanted. A gradual decrease in the size of the
signal intensity was apparent at post 7 days while striking differences
were not noted between post 7 and 14 days
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The second goal of this study was to observe the engraft-
ment of ferumoxytol-labeled hUCB-MSCs at the target site.
As expected, iron-positive hUCB-MSCs were accurately de-
livered and engrafted into the mouse hippocampus. Growth of
the transplanted cells was not examined in depth because
MSCs have a low probability of proliferating in vivo, which
is probably why they do not generate teratomas unlike embry-
onic and induced pluripotent stem cells [46, 47]. Considering
the aggregated state of the cells, limited distribution seem to
have occurred for both unlabeled and ferumoxytol-labeled
hUCB-MSCs. Compared to the left hippocampus (unlabeled
hUCB-MSCs as a control), a prominent negative contrast was
discernible from the right hippocampus where ferumoxytol-
labeled hUCB-MSCs were injected. Such hypointense signals
were visualized at various time points from immediately to
post 14 days following stereotactic delivery. In contrast to
the T2-weighted images, the enlarged areas of dark signals
in the T2* GRE images are representative of the blooming
effect or susceptibility artifacts which decreased with time
[48]. While T2 weighted spin echo lacks iron sensitivity,
T2* is much more sensitive but does not provide a reliable
representation of the engraftment size. Thus, the two se-
quences compensate for each other’s weaknesses and were
both used to noninvasively image the engraftment site.
Other than the blooming effect, alternative confounding
factors that may restrict the interpretation of MR images in-
clude (but are not limited to) brain puncture, hemorrhage, and
activation of macrophages. First, signs of hemorrhages were
not recognized from MR images, which excluded bleeding as
a source of the negative signal. Based on the images of the
sham group, the hypointense signal was generated from pen-
etration of the needle into the brain parenchyma and clearly
differed from that created from the injection of ferumoxytol-
labeled hUCB-MSCs [49, 50]. An interesting observation was
that infiltration of inflammatory cells was not detected at the
sites of engraftment for either unlabeled or ferumoxytol-
labeled hUCB-MSCs. This indicated that macrophage engulf-
ment of iron and/or dead cells were not the origin of the
hypointensity [51]. However, former groups have proposed
that SPIO-labeled cells underwent apoptosis and phagocytosis
by macrophages when observed as early as 1 to 2 weeks post
transplantation [51–54]. Considering such reports, we cannot
rule out the possibility that apoptosis and inflammatory cell
infiltration might be apparent as was as reduced cell survival
at the site of ferumoxytol-labeled hUCB-MSC engraftment if
monitored at later time points past 1 day.
This study has several limitations that must be discussed.
First, as stated above, cell fate was not evaluated at time points
past one day. However the gradual decrease in hypointensity
observed over time is suggested to be indicative of cell sur-
vival [26]. Thus, we expect the residual, viable cells from the
initial transplantation to contribute to the generation of the
hypointense signal. Second, the efficacy of the ferumoxytol-
labeled hUCB-MSCs in the transgenic AD mouse model was
not examined in depth. The major aims of our study were to
assess the feasibility of labeling hUCB-MSCs with
ferumoxytol and their detection using MRI. As a result, po-
tential therapeutic benefits or biological roles of ferumoxytol-
labeled hUCB-MSCs in the host environment were not exten-
sively investigated. Since the ferumoxytol-labeled hUCB-
MSCs met the criteria proposed by the ISCT, we presume that
the labeled cells would not fall short of the stemness, includ-
ing immunophenotype and therapeutic potential, displayed by
unlabeled, naïve MSCs. Further study is warranted to evaluate
the efficacy of ferumoxytol-labeled hUCB-MSCs, their sur-
vival, and its correlation to the persistence of negative signals
detected from MRI.
In summary, the results from the current study introduce
use of the heparin-protamine sulfate-ferumoxytol
nanocomplex to label hUCB-MSCs and show that labeled
cells can be detected noninvasively using MRI following
transplantation. We hope that this method will be applied as
a follow-up for clinical cell transplantations not only in AD,
but also in various other diseases.
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